ICAM1 and metabolic dysfunction-associated steatohepatitis: In summary, we have shown that ICAM-1 has no impact on WD-induced body fat gain, protects from systemic glucose tolerance and differentially alters local tissue inflammation by ameliorating adipose tissue inflammation and partially aggravating MASH progression.